{"database":"panorama","file_versions":[],"scores":{"citationCount":0,"reanalysisCount":0,"viewCount":0,"searchCount":0},"additional":{"omics_type":["Proteomics"],"submitter":["Fredrik Edfors"],"species":["Homo Sapiens"],"full_dataset_link":["https://panoramaweb.org/longitudinalplasmaprofiling.url"],"submitter_email":["fredrik.edfors@scilifelab.se"],"submitter_affiliation":["Science For Life Laboraotry"],"sample_protocol":[""],"repository":["PanoramaPublic"],"data_protocol":[""],"pubmed_abstract":["Spike-in of standards of known concentrations used in proteomics-based workflows is an attractive approach for both accurate and precise multiplexed protein quantification. Here, a quantitative method based on targeted proteomics analysis of plasma proteins using isotope-labeled recombinant standards originating from the Human Protein Atlas project has been established. The standards were individually quantified prior to being employed in the final multiplex assay. The assays are mainly directed toward actively secreted proteins produced in the liver, but may also originate from other parts of the human body. This study included 21 proteins classified by the FDA as either drug targets or approved clinical protein biomarkers. We describe the use of this multiplex assay for profiling a well-defined human cohort with sample collection spanning over a one-year period. Samples were collected at four different time points, which allowed for a longitudinal analysis to assess the variable plasma proteome within individuals. Two assays toward APOA1 and APOB had available clinical data, and the two assays were benchmarked against each other. The clinical assay is based on antibodies and shows high correlation between the two orthogonal methods, suggesting that targeted proteomics with highly parallel, multiplex analysis is an attractive alternative to antibody-based protein assays."],"pubmed_title":["Longitudinal Plasma Protein Profiling Using Targeted Proteomics and Recombinant Protein Standards."],"pubmed_authors":["Kotol David D, Hunt Helian H, Hober Andreas A, Karlsson Max J MJ, Forsström Björn B, Gummesson Anders A, Bergström Göran G, Fagerberg Linn L, Uhlén Mathias M, Edfors Fredrik F"],"description_synonyms":["Biological Markers, Viral Marker, Surrogate Endpoints, Product, Brp-14, determination, Laboratory, Blood, Biochemical, Human Figures, Endpoint, apob-100, protein, B-cell receptor complex, Serum, Long Term, Proapolipoprotein A-I, Apolipoprotein A1, Techniques, Laboratory Markers, sampling, Method, Biological, Pharmaceutical Product, Alp-1, protein aggregate, Effect, Fresh Frozen Plasmas, Fresh Frozen, Man (Taxonomy), membrane bound, C1, iecur, Parts, procedures, AI315052, Body Parts and Fluids, Apo-AI, ApoB, Immune, Markers, Methodological Studies, medicine, scientific observation, Pharmaceutical, Viral Markers, Figure, Human Bodies, Body Parts, Lvtw-1, Apolipoprotein A-I(1-242), B-lymphocyte receptor complex, Reference Standard, Long-Term Effects, plasma, Apo-B, apoA-I, Standard Preparation, Standard Preparations, Frozen Plasma, Standardization, Viral, Surrogate Endpoint, Apoa-1, Modern, Longterm Effect, Biochemical Markers, Procedure, antibodies, Plasmas, Biologic Marker, LDLCQ4, Sep-2, Menstruation, Sep-1, Marker, Pharmaceutic, End Points, Standard, Methodological, Immunologic, Laboratory Marker, Methodological Study, human, Atlases, immunoglobulin, B cell receptor accessory molecule complex, Biochemical Marker, B lymphocyte receptor complex, ApoA-I, Proteomes, Fresh, criteria, human being, Procedures, Fresh Frozen Plasma, ProapoA-I, Peptidomics, Bodies, Clinical Markers, Effects, Clinical Marker, number, Gene, apo-AI, guidelines, protein-containing complex, presence, Human, jecur, Surrogate End Points, Surrogate Markers, antibody, method, BCR complex, Homo sapiens, method used in an experiment, Gene Products, Studies, immunoglobulin complex, Technique, Man, Drugs, study, Biomarker, Blood Plasma, Clinical, Longterm, apob-48, apolipoprotein A1, Biological Marker, Long-Term, Study, drugs, Immunologic Markers, Reference, Truncated apolipoprotein A-I, Blood Plasmas, Apoprotein (B), Long-Term Effect, Preparation, Apoproteins B, Immunologic Marker, Biologic, Pharmaceuticals, measuring, Products, protein complex, drug, Proteins, Serum Markers, End Point, total expressed protein, Sep2, Immune Marker, Frozen Plasmas, Isotope, count in organism, native protein, Period, APOA1, Surrogate End Point, Protein, chemical analysis, Long Term Effects, techniques, specimen collection, Biologic Markers, opsonin activity, Plasma, Serum Marker, Pharmaceutic Preparations, Protein., Surrogate, Apo B-100, Endpoints, portion of plasma, Human Figure, Ltw-1, Body, Surrogate Marker, Longterm Effects, Protein Gene Products, plan specification, Drug, Gene Proteins, Livers, Preparations, FLDB, sample collection, Apo B, Figures, Modern Man, Standards, B cell receptor activity, assay, variable, Pharmaceutical Products, Pharmaceutical Preparation, methodology, Immune Markers"],"pubmed_title_synonyms":["Protein Gene Products, Gene Proteins, Standard Preparation, Standard Preparations, Preparations, Reference, criteria, Standardization, native protein, Standard, Peptidomics, protein complex, Protein, Standards, Gene Products, Proteins, Gene, Preparation, protein, protein aggregate, guidelines, protein-containing complex, Reference Standard, Standards."],"name_synonyms":["Protein Gene Products, Gene Proteins, Standard Preparation, Standard Preparations, Preparations, Reference, criteria, Standardization, native protein, Standard, Peptidomics, protein complex, Protein, Standards, Gene Products, Proteins, Gene, Preparation, protein, protein aggregate, guidelines, protein-containing complex, Reference Standard, Standards."],"pubmed_abstract_synonyms":["Biological Markers, Viral Marker, Surrogate Endpoints, Product, Brp-14, determination, Laboratory, Blood, Biochemical, Human Figures, Endpoint, apob-100, protein, B-cell receptor complex, Serum, Long Term, Proapolipoprotein A-I, Apolipoprotein A1, Techniques, Laboratory Markers, sampling, Method, Biological, Pharmaceutical Product, Alp-1, protein aggregate, Effect, Fresh Frozen Plasmas, Fresh Frozen, Man (Taxonomy), membrane bound, C1, iecur, Parts, procedures, AI315052, Body Parts and Fluids, Apo-AI, ApoB, Immune, Markers, Methodological Studies, medicine, scientific observation, Pharmaceutical, Viral Markers, Figure, Human Bodies, Body Parts, Lvtw-1, Apolipoprotein A-I(1-242), B-lymphocyte receptor complex, Reference Standard, Long-Term Effects, plasma, Apo-B, apoA-I, Standard Preparation, Standard Preparations, Frozen Plasma, Standardization, Viral, Surrogate Endpoint, Apoa-1, Modern, Longterm Effect, Biochemical Markers, Procedure, antibodies, Plasmas, Biologic Marker, LDLCQ4, Sep-2, Menstruation, Sep-1, Marker, Pharmaceutic, End Points, Standard, Methodological, Immunologic, Laboratory Marker, Methodological Study, human, Atlases, immunoglobulin, B cell receptor accessory molecule complex, Biochemical Marker, B lymphocyte receptor complex, ApoA-I, Proteomes, Fresh, criteria, human being, Procedures, Fresh Frozen Plasma, ProapoA-I, Peptidomics, Bodies, Clinical Markers, Effects, Clinical Marker, number, Gene, apo-AI, guidelines, protein-containing complex, presence, Human, jecur, Surrogate End Points, Surrogate Markers, antibody, method, BCR complex, Homo sapiens, method used in an experiment, Gene Products, Studies, immunoglobulin complex, Technique, Man, Drugs, study, Biomarker, Blood Plasma, Clinical, Longterm, apob-48, apolipoprotein A1, Biological Marker, Long-Term, Study, drugs, Immunologic Markers, Reference, Truncated apolipoprotein A-I, Blood Plasmas, Apoprotein (B), Long-Term Effect, Preparation, Apoproteins B, Immunologic Marker, Biologic, Pharmaceuticals, measuring, Products, protein complex, drug, Proteins, Serum Markers, End Point, total expressed protein, Sep2, Immune Marker, Frozen Plasmas, Isotope, count in organism, native protein, Period, APOA1, Surrogate End Point, Protein, chemical analysis, Long Term Effects, techniques, specimen collection, Biologic Markers, opsonin activity, Plasma, Serum Marker, Pharmaceutic Preparations, Protein., Surrogate, Apo B-100, Endpoints, portion of plasma, Human Figure, Ltw-1, Body, Surrogate Marker, Longterm Effects, Protein Gene Products, plan specification, Drug, Gene Proteins, Livers, Preparations, FLDB, sample collection, Apo B, Figures, Modern Man, Standards, B cell receptor activity, assay, variable, Pharmaceutical Products, Pharmaceutical Preparation, methodology, Immune Markers"],"citation_count":["0"],"additional_accession":[]},"is_claimable":false,"name":"Longitudinal Protein Profiling using Targeted Proteomics and Recombinant Standards","description":"Spike-in of standards of known concentrations used in proteomics-based workflows is an attractive approach for both accurate and precise multiplexed protein quantification. Here, a quantitative method based on targeted proteomics analysis of plasma proteins using isotope-labelled recombinant standards originating from the Human Protein Atlas project has been established. The standards were individually quantified prior to being employed in the final multiplex assay. The assays are mainly directed towards actively secreted proteins produced in the liver, but may also originate from other parts of the human body. This study included 21 proteins classified by FDA as either drug targets or approved clinical protein biomarkers. We describe the use of this multiplex assay for profiling a well-defined human cohort with sample collection spanning over a one-year period. Samples were collected at four different time points which allowed for a longitudinal analysis to assess the variable plasma proteome within individuals. Two assays towards APOA1 and APOB had available clinical data and the two assays were benchmarked against each other. The clinical assay is based on antibodies and shows high correlation between the two orthogonal methods suggesting that targeted proteomics with highly parallel, multiplex analysis is an attractive alternative to antibody-based protein assays.","dates":{"publication":"Mon Mar 15 00:00:00 GMT 2021"},"accession":"PXD020797","cross_references":{"TAXONOMY":["9606"],"pubmed":["32820635"]}}